However, it remains to be demonstrated whether the therapeutic effect of HDAC6 inhibition is only relevant for patients with a mutation in HSPB1, or whether it can be extrapolated to other forms of CMT2, or even to CMT1. Here, HDAC6 is linked to Charcot-Marie-Tooth disease type 1.